Invex Therapeutics (Australia) Buy Hold or Sell Recommendation
| IXC Stock | 0.07 0 4.29% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Invex Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Invex Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Invex Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Invex Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Invex and provide practical buy, sell, or hold advice based on investors' constraints. Invex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Invex |
Execute Invex Therapeutics Buy or Sell Advice
The Invex recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Invex Therapeutics. Macroaxis does not own or have any residual interests in Invex Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Invex Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Invex Therapeutics Trading Alerts and Improvement Suggestions
| Invex Therapeutics generated a negative expected return over the last 90 days | |
| Invex Therapeutics has some characteristics of a very speculative penny stock | |
| Invex Therapeutics has high historical volatility and very poor performance | |
| The company reported the revenue of 1.21 M. Net Loss for the year was (1.64 M) with profit before overhead, payroll, taxes, and interest of 459.08 K. | |
| Invex Therapeutics generates negative cash flow from operations | |
| About 68.0% of the company shares are held by company insiders |
Invex Therapeutics Returns Distribution Density
The distribution of Invex Therapeutics' historical returns is an attempt to chart the uncertainty of Invex Therapeutics' future price movements. The chart of the probability distribution of Invex Therapeutics daily returns describes the distribution of returns around its average expected value. We use Invex Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Invex Therapeutics returns is essential to provide solid investment advice for Invex Therapeutics.
| Mean Return | -0.01 | Value At Risk | -5 | Potential Upside | 4.17 | Standard Deviation | 3.31 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Invex Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Invex Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 14.1M | 6.4M | (3.4M) | (6.9M) | (16.4M) | (15.6M) | |
| Free Cash Flow | (1.6M) | (1.7M) | (3.4M) | (6.9M) | (2.4M) | (2.6M) | |
| Change In Working Capital | 661.5K | 95.7K | (124.5K) | (187.9K) | (902.2K) | (857.1K) | |
| Begin Period Cash Flow | 12.2M | 26.3M | 32.7M | 29.3M | 22.5M | 18.1M | |
| Other Non Cash Items | 112.0K | (52.7K) | 348.6K | 588.0K | (802.2K) | (762.1K) | |
| Total Cash From Operating Activities | (1.6M) | (1.7M) | (3.4M) | (6.9M) | (2.4M) | (2.6M) | |
| Change To Account Receivables | 36.5K | 95.7K | (124.5K) | (187.9K) | 238.6K | 250.5K | |
| Net Income | (3.4M) | (2.3M) | (4.0M) | (7.7M) | (1.6M) | (1.7M) | |
| End Period Cash Flow | 26.3M | 32.7M | 29.3M | 22.5M | 6.0M | 5.7M |
Invex Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Invex Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Invex Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Invex stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.08 | |
β | Beta against Dow Jones | 0.48 | |
σ | Overall volatility | 3.36 | |
Ir | Information ratio | -0.04 |
Invex Therapeutics Volatility Alert
Invex Therapeutics exhibits very low volatility with skewness of 1.35 and kurtosis of 11.93. Invex Therapeutics is a penny stock. Although Invex Therapeutics may be in fact a good investment, many penny stocks are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Invex Therapeutics. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Invex instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Invex Therapeutics Fundamentals Vs Peers
Comparing Invex Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Invex Therapeutics' direct or indirect competition across all of the common fundamentals between Invex Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Invex Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Invex Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Invex Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Invex Therapeutics to competition |
| Fundamentals | Invex Therapeutics | Peer Average |
| Return On Equity | -0.12 | -0.31 |
| Return On Asset | -0.0922 | -0.14 |
| Profit Margin | (1.35) % | (1.27) % |
| Operating Margin | 0.29 % | (5.51) % |
| Current Valuation | (989.76 K) | 16.62 B |
| Shares Outstanding | 75.15 M | 571.82 M |
| Shares Owned By Insiders | 67.72 % | 10.09 % |
| Price To Book | 0.89 X | 9.51 X |
| Price To Sales | 4.15 X | 11.42 X |
| Revenue | 1.21 M | 9.43 B |
| Gross Profit | 459.08 K | 27.38 B |
| EBITDA | (720.44 K) | 3.9 B |
| Net Income | (1.64 M) | 570.98 M |
| Total Debt | 431.63 K | 5.32 B |
| Book Value Per Share | 0.08 X | 1.93 K |
| Cash Flow From Operations | (2.44 M) | 971.22 M |
| Earnings Per Share | (0.02) X | 3.12 X |
| Beta | 0.41 | -0.15 |
| Market Capitalization | 5.04 M | 19.03 B |
| Total Asset | 6.12 M | 29.47 B |
| Retained Earnings | (19.22 M) | 9.33 B |
| Working Capital | 5.69 M | 1.48 B |
| Annual Yield | 2.78 % | |
| Net Asset | 6.12 M |
Invex Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Invex . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 0.067 | |||
| Day Typical Price | 0.067 | |||
| Price Action Indicator | (0) | |||
| Period Momentum Indicator | (0) |
About Invex Therapeutics Buy or Sell Advice
When is the right time to buy or sell Invex Therapeutics? Buying financial instruments such as Invex Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Invex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ISP Thematic Idea Now
ISP
Internet Service Providers (ISP) companies and IT providers specializing in internet technologies. The ISP theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ISP Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.